DNA Damage Repair Therapy is a biomarker-driven treatment strategy that targets impaired DNA repair mechanisms in neurodegenerative diseases. Elevated DNA damage markers guide therapy selection and monitoring.
Neurons are particularly vulnerable to DNA damage due to high metabolic activity and limited regenerative capacity. Accumulation of DNA lesions contributes to neuronal dysfunction and cell death in AD, PD, and other neurodegenerative conditions.
- Base excision repair enhancement - PARP1/2 modulators
- Nucleotide excision repair support - XPA-XPC pathway activators
- DNA strand break repair - ATM/ATR pathway modulators
- Mitochondrial DNA protection - mtDNA repair enhancers
| Biomarker |
Target |
Measurement Method |
Expected Change |
| 8-OHdG (urine) |
Decrease |
LC-MS/MS |
40-60% reduction |
| 8-OHdG (CSF) |
Decrease |
ELISA |
30-50% reduction |
| gamma-H2AX |
Decrease |
Flow cytometry |
50-70% reduction |
| PAR levels |
Normalize |
ELISA |
Return to baseline |
| Telomere length |
Stabilize |
qPCR |
Prevent shortening |
- Marker of: Oxidative DNA damage
- Elevated in: AD, PD, ALS, Huntington's
- Correlation: Disease severity and progression
- Marker of: DNA double-strand breaks
- Elevated in: Ataxia telangiectasia, AD
- Therapeutic target: ATM pathway activation
- Marker of: PARP activation (DNA repair attempt)
- Elevated in: Neurodegeneration
- Therapeutic target: PARP inhibition
- Elevated baseline 8-OHdG (>10 ng/mL in urine)
- Evidence of DNA repair impairment
- Diagnosis of AD, PD, HD, or ALS
- Age 50-80 years
¶ Therapeutic Candidates
- Olaparib - FDA-approved for cancer
- Niraparib - CNS penetration
- Rucaparib - Small molecule
- Nicotinamide riboside - NAD+ precursor
- Resveratrol - SIRT1 activator
- PQQ - Mitochondrial biogenesis
- Edaravone - Free radical scavenger
- CoQ10 - Mitochondrial protection
- Methylene blue - Oxidative stress reducer
- Screen for elevated 8-OHdG or gamma-H2AX
- Confirm DNA damage phenotype
- Stratify by oxidative stress markers
- Interim DNA damage biomarker analysis at 3 months
- Dose adjustment based on biomarker response
- Biomarker-guided patient stratification
- Primary: Change in urinary 8-OHdG at 12 months
- Secondary: Cognitive/motor scores, brain atrophy
| Timepoint |
Urine 8-OHdG |
CSF 8-OHdG |
PAR Levels |
Clinical |
| Baseline |
Required |
Optional |
Required |
Required |
| 3 months |
Required |
- |
Optional |
Required |
| 6 months |
Required |
Required |
Required |
Required |
| 12 months |
Required |
Required |
Required |
Required |
- BBB penetration - Many PARP inhibitors limited
- Therapeutic window - PARP inhibition vs activation
- Biomarker variability - 8-OHdG affected by diet/exercise
- Chronic vs acute - Long-term treatment unknown
- PARP + NAD+ precursor - Synergistic DNA repair
- Antioxidant + PARP inhibitor - Reduce oxidative damage + enhance repair
- Mitochondrial + nuclear DNA - Target both compartments
- Blood-based DNA damage markers
- Gene therapy for DNA repair enzymes
- Personalized DNA damage profiles